Clinical Characteristics of Patients Requiring Emergency Hospitalization Due to Immune-related Adverse Events: a Retrospective Study

Overview

Journal J Pharm Health Care Sci

Publisher Biomed Central

Specialty Pharmacology

Date 2024 Dec 19

PMID 39696701

Authors

Tatsuki Ikeda

Satoru Nihei

Kazuki Saito

Junichi Asaka

Kenzo Kudo

Affiliations

Soon will be listed here.

Abstract

Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, offering hope for various malignancies by enhancing the immune response against tumors. However, ICIs are associated with unique immune-related adverse events (irAEs), which differ significantly from conventional chemotherapy-induced toxicities. These irAEs, which affect more than 70% of patients and often escalate to severe grades, present substantial clinical management challenges and frequently necessitate emergency hospitalization. Therefore, this study aimed to investigate the clinical characteristics of patients requiring emergency hospitalization due to irAEs during ICI therapy to enhance understanding and improve management strategies.

Methods: This retrospective study evaluated patients who received ICIs at Iwate Medical University Hospital between August 1, 2016, and December 31, 2022, and required emergency hospitalization due to irAEs. Clinical data were extracted from the medical records, including patient demographics, presenting complaints, time from ICI initiation to hospitalization, irAE diagnoses, and treatment outcomes. The Spearman rank correlation coefficient was used to analyze the associations between the chief complaints and irAE diagnoses.

Results: Of 1009 ICI-treated patients, 96 required emergency hospitalization for irAEs. The cohort's mean age was 73 years, with 75.0% of patients being male. Among patients who required emergency hospitalization, a high proportion were undergoing treatment for lung cancer (41.7%). The median hospitalization duration was 87 days. The chief complaints included dyspnea (34.4%) and fatigue (34.4%), with gastrointestinal and respiratory disorders being the most frequent irAEs (35.4%). Significant correlations were observed between dyspnea and respiratory diseases (Rs = 0.66), skin diseases and disorders (Rs = 0.81), pain and musculoskeletal disorders (Rs = 0.59), and diarrhea and gastrointestinal disorders (Rs = 0.49). Corticosteroids were administered to 64.6% of the patients. Despite emergency interventions, 8.3% of patients succumbed to irAEs, while 33.3% resumed ICI therapy after hospitalization.

Conclusions: Emergency hospitalization due to irAEs is a considerable concern in ICI therapy, occurring in 9.5% of treated patients. The high incidence of severe irAEs within the first 3 months of treatment underscores the need for early and vigilant monitoring. This study highlights the importance of recognizing and promptly managing irAEs to improve patient outcomes. Future strategies should focus on developing comprehensive management frameworks and enhancing patient and caregiver education to recognize symptoms that warrant immediate medical attention.

References

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Castillo R, Sandefur B, Finch A, Richter M, Thanarajasingam U . Clinical Presentations and Outcomes of Patients Receiving Immune Checkpoint Inhibitors Presenting to the Emergency Department. Mayo Clin Proc Innov Qual Outcomes. 2021; 5(6):1029-1035. PMC: 8569628. DOI: 10.1016/j.mayocpiqo.2021.09.007. View

Grauer A, Cornelius T, Abdalla M, Moise N, Kronish I, Ye S . Impact of early telemedicine follow-up on 30-Day hospital readmissions. PLoS One. 2023; 18(5):e0282081. PMC: 10202267. DOI: 10.1371/journal.pone.0282081. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Michot J, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S . Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016; 54:139-148. DOI: 10.1016/j.ejca.2015.11.016. View

Yin Q, Wu L, Han L, Zheng X, Tong R, Li L . Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023; 14:1167975. PMC: 10247998. DOI: 10.3389/fimmu.2023.1167975. View

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey C, Lao C . Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1):23-34. PMC: 5698905. DOI: 10.1056/NEJMoa1504030. View

Wood L, Moldawer N, Lewis C . Immune Checkpoint Inhibitor Therapy: Key Principles When Educating Patients. Clin J Oncol Nurs. 2019; 23(3):271-280. DOI: 10.1188/19.CJON.271-280. View

Weber J, Kahler K, Hauschild A . Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012; 30(21):2691-7. DOI: 10.1200/JCO.2012.41.6750. View

10.

Falade A, Zubiri L, Wu C, Perlman K, Sun J, Hathaway N . Immune-related adverse events requiring hospitalization in patients with lung cancer: implications and insights. Oncologist. 2024; 29(11):e1615-e1620. PMC: 11546633. DOI: 10.1093/oncolo/oyae189. View

11.

Poto R, Troiani T, Criscuolo G, Marone G, Ciardiello F, Tocchetti C . Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Front Immunol. 2022; 13:804597. PMC: 9005797. DOI: 10.3389/fimmu.2022.804597. View

12.

Guven D, Sahin T, Aksun M, Taban H, Aktepe O, Aksu N . Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors. Support Care Cancer. 2020; 29(4):2029-2035. DOI: 10.1007/s00520-020-05702-8. View

13.

Brahmer J, Lacchetti C, Thompson J . Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2018; 14(4):247-249. DOI: 10.1200/JOP.18.00005. View

14.

Cella D, Davis K, Breitbart W, Curt G . Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. 2001; 19(14):3385-91. DOI: 10.1200/JCO.2001.19.14.3385. View

15.

Lipson E, Sharfman W, Drake C, Wollner I, Taube J, Anders R . Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2012; 19(2):462-8. PMC: 3548952. DOI: 10.1158/1078-0432.CCR-12-2625. View

16.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

17.

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J . Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017; 18(3):312-322. DOI: 10.1016/S1470-2045(17)30065-7. View

18.

Holstead R, Kartolo A, Baetz T . Emergency Department Utilization for Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis of Identification and Outcomes for Those Presenting for Immune-Related Adverse Events. Curr Oncol. 2021; 28(1):52-59. PMC: 7816173. DOI: 10.3390/curroncol28010007. View

19.

Naing A, Hajjar J, Gulley J, Atkins M, Ciliberto G, Meric-Bernstam F . Strategies for improving the management of immune-related adverse events. J Immunother Cancer. 2020; 8(2). PMC: 7735083. DOI: 10.1136/jitc-2020-001754. View

20.

Ozdemir B, Espinosa da Silva C, Arangalage D, Monney P, Guler S, Huynh-Do U . Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients. Cancer Immunol Immunother. 2023; 72(7):1991-2001. PMC: 10264466. DOI: 10.1007/s00262-023-03436-0. View